Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
Overview
AngioDynamics Inc is a Nasdaq-listed public company renowned for designing, manufacturing, and selling a broad portfolio of innovative medical devices that serve diverse clinical applications. With deep expertise in the fields of oncology, interventional radiology, and vascular surgery, the company focuses on the minimally invasive treatment of diseases such as peripheral vascular disorders and cancer. Industry-specific keywords such as "minimally invasive procedures", "diagnostic devices", and "interventional radiology" underscore the company’s commitment to technological innovation.
Core Business and Operations
The company operates by providing a comprehensive range of devices which include systems for radiofrequency ablation, vascular access, angiographic procedures, dialysis support, angioplasty, drainage, thrombolysis, embolization, and venous treatments. These products are designed for use in clinical settings by interventional radiologists, surgeons, and nephrologists. Through its diverse product line, AngioDynamics is able to offer end-to-end solutions that enhance procedural efficiency and patient outcomes. The revenue model primarily relies on direct sales to healthcare institutions, supported by a strong service network ensuring reliability and continued product support.
Market Position and Competitive Landscape
AngioDynamics has distinguished itself in a technologically competitive and high-growth industry. By investing in research and development, the company has maintained its ability to continuously bring forward new technologies and improve existing products. This commitment to innovation positions the company among notable competitors in the medical device industry. Its competitive differentiation stems from a consistent track record of product innovation, robust clinical performance, and strategic market presence. The company's market position is further bolstered by its focused approach to addressing specialized clinical needs and its ability to integrate advanced technological solutions into traditional treatment paradigms.
Product Portfolio and Technological Innovation
The product portfolio of AngioDynamics spans a wide range of medical device categories. From advanced radiofrequency ablation systems to precision surgical tools, the company leverages cutting-edge technology to develop devices that offer improved safety profiles and enhanced procedural outcomes. Emphasis on 'innovative technology' and 'minimally invasive procedures' highlights the company’s pursuit of excellence in device performance. Each product category is built on comprehensive clinical insights and a deep understanding of procedural requirements, ensuring that healthcare providers are equipped with devices that cater to their diagnostic and therapeutic needs.
Operational Excellence and Industry Expertise
AngioDynamics demonstrates operational excellence by aligning its product development with the evolving needs of healthcare providers. The company’s strategic focus on clinical innovation and rigorous quality control reflects its deep industry expertise and commitment to delivering reliable and effective medical solutions. Structured research programs, continuous product improvements, and a robust post-market support system underpin the company’s reputation for innovation and operational excellence. This integrated approach assists healthcare professionals in achieving improved outcomes while ensuring safety and compliance under constantly evolving medical standards.
Strategic Business Model and Value Proposition
Central to AngioDynamics' value proposition is the delivery of solutions that advance the standard of care in critical clinical procedures. The company’s business model is built around the continuous enhancement of product performance and the facilitation of minimally invasive therapeutic options. By maintaining a deep focus on quality and usability, AngioDynamics provides a reliable partnership for medical institutions seeking to integrate innovative device technologies. This strategic alignment with frontline clinical needs makes the company a noteworthy reference point for discussions on medical innovation, procedural efficiency, and enhanced patient care.
Industry Impact and Long-Term Relevance
With a rich history dating back to its founding in 1988, AngioDynamics has consistently contributed to medical advancements through its innovative product solutions. The company's impact on the healthcare industry is visible across multiple clinical areas, reinforcing its role as a significant player in medical technology. The enduring relevance of its products and the clarity of its market focus ensures that AngioDynamics remains a principal component in the discussion of medical device innovation and procedural technology. This comprehensive approach, combined with clear communication and expert-driven design, continues to shape the narrative around modern, efficient, and effective clinical practices.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q4 and fiscal year 2021 on July 13, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET for management to discuss these results. Investors can dial in using a specified number or access through a webcast on the company's website. Additionally, AngioDynamics will host a virtual Investor & Technology Day on the same day at 9:30 a.m. ET. Details and registration information will be provided on their website.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that it received 510(k) clearance from the FDA for the AlphaVac Mechanical Thrombectomy System, designed for non-surgical removal of thrombi or emboli. The commercial release is anticipated in the second half of 2021. Additionally, the Company will report its fourth quarter and fiscal year 2021 financial results on July 13, 2021, with a conference call scheduled at 8:00 a.m. ET, followed by a virtual Investor and Technology Day at 9:30 a.m. ET.
AngioDynamics, Inc. (NASDAQ: ANGO), a top provider of minimally invasive medical devices, announced Jim Clemmer, President and CEO, will present at the UBS Virtual Global Healthcare Conference on May 25, 2021, at 12:00 p.m. ET. The live webcast can be accessed through the company’s website and will be available for replay afterward.
The company specializes in devices for vascular access, peripheral vascular disease, and oncology, with a product range that includes ablation systems and drainage products. For further details, visit www.angiodynamics.com.
AngioDynamics (NASDAQ: ANGO) announced the submission of a 510(k) application to the FDA for its AlphaVac System on April 9, 2021. This innovative thrombectomy device aims to treat undesirable intravascular materials in the venous system and peripheral vasculature. The AlphaVac System combines a mechanical aspiration handle with a self-expanding funnel tip, enhancing control and minimizing blood loss during procedures. The company anticipates the release of AlphaVac in the latter half of 2021, pending FDA clearance, as part of its strategy to expand its thrombus management portfolio.
AngioDynamics (NASDAQ:ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Needham Virtual Healthcare Conference on April 12, 2021, at 8:45 a.m. ET. Investors can access the live webcast through AngioDynamics’ website, where a replay will also be available post-event. The company specializes in products for vascular access, peripheral vascular disease, and oncology, including ablation systems and vascular access products.
AngioDynamics (NASDAQ: ANGO) reported its third-quarter fiscal 2021 financial results, showing a 2% year-over-year revenue growth to $71.2 million, despite COVID-19 challenges. Vascular Interventions and Therapies sales increased by 8.8% to $33.3 million. However, Oncology sales dropped by 10.1% to $13.1 million. The company recorded a net loss of $3.5 million, improving from a $5.7 million loss last year. The gross margin declined to 54.1% due to Auryon start-up costs and COVID-related impacts. Adjusted guidance for FY2021 is now $285-$288 million in sales.
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will take part in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum. The event is scheduled for 10:00 a.m. ET on March 24, 2021. Investors can access a live webcast through the company’s website, with replay availability post-event. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, offering a range of leading products.
AngioDynamics, Inc. (NASDAQ: ANGO) announces participation in a virtual fireside chat at the 31st Annual Oppenheimer Healthcare Conference. Scheduled for March 16, 2021, at 9:20 a.m. ET, CEO Jim Clemmer and CFO Stephen Trowbridge will discuss company insights. A live webcast will be available through the Company’s website, with replay options post-event. AngioDynamics specializes in innovative, minimally invasive medical devices for vascular access, oncology, and peripheral vascular disease, focusing on diverse product lines that enhance patient care.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 FY2021 on March 30, 2021, before the market opens. Management will host a conference call at 8:00 a.m. ET to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13717367. The call will also be available via webcast on the AngioDynamics website, with a replay accessible shortly after the call concludes.
AngioDynamics, a leader in minimally invasive medical devices, has announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Barclays Virtual Global Healthcare Conference on March 9, 2021, at 8:00 a.m. ET. Investors can access a live webcast of the presentation through the Company’s website, with a replay available later. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, offering a range of products including ablation systems and thrombolytic products.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
What does AngioDynamics specialize in?
How does AngioDynamics generate its revenue?
What are the key product categories offered by AngioDynamics?
How does AngioDynamics differentiate itself from competitors?
Who are the primary customers of AngioDynamics?
What is the significance of minimally invasive procedures in their product development?
How does the company maintain its industry expertise?
What role does innovation play in AngioDynamics' business model?
